ACRS

Rating neutralAI Memo

Aclaris Therapeutics

As of 2026-05-27/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-27 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 results and cash-runway update • 2026-05-07

Expected move: +5%

Biggest risk

If the readouts underwhelm or slip, Aclaris could revert to a low-multiple, cash-runway story with limited diversification and persistent dilution overhang, which would compress the upside implied by the packet’s target summary.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

If ATI-052 and bosakitug both continue to advance, the market can re-rate Aclaris on pipeline optionality while the reported cash runway through end-2028 reduces immediate financing pressure [#8-K-2026-05-07].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-27

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ATI-052 Phase 1b asthma and atopic dermatitis readouts
Bosakitug Phase 2 atopic dermatitis topline
If ATI-052 and bosakitug both continue to advance, the market can re-rate Aclaris on pipeline optionality while the reported cash runway through end-2028 reduces immediate financing pressure [#8-K-2026-05-07].

BearKey bullets

Clinical execution risk: ATI-052 and bosakitug both need clean efficacy/safety data to justify further rerating.
Financing and dilution risk remain present even with the reported runway, because development spend can rise if programs advance or expand.
Low coverage and no verified post-print analyst revision signal leave the market with limited external validation of the thesis.

WatchKey bullets

Q1 2026 results and cash-runway update

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=55%)

Bull/Bear spread: +82% / -41%

Vs latest close: Bull +82% · Base +5% · Bear -41%

Scenario probabilities

Bull Target: $8 (p=20%)Base Target: $5 (p=55%)Bear Target: $3 (p=25%)

Commentary

Primary-source tone is constructive but still monitoring-oriented: the May 7 release highlighted a long cash runway and upcoming readouts, yet the packet contains no fresh analyst revisions and no verified post-print price-reaction data, so conviction should stay modest rather than aggressive.

As of 2026-05-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ATI-052 Phase 1b asthma and atopic dermatitis readouts
Bosakitug Phase 2 atopic dermatitis topline

Scenarios

Bull Target (Scenario probability)

$8 / p=20% prob

Base Target (Scenario probability)

$5 / p=55% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Price $5 as of 2026-05-28

Nearest Scenario: Base (∆ 5%)

Targets vs latest close: Bull +82% · Base +5% · Bear -41%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-07
Q1 2026 results and cash-runway update
The May 7 8-K/press release reported Q1 2026 revenue of $2.0M, net loss of $19.8M, R&D expense of $15.7M, and cash, cash equivalents and marketable securities of $190.8M, with management saying runway extends through the end of 2028; that keeps near-term dilution pressure contained but leaves valuation dependent on pipeline execution [#8-K-2026-05-07].
Prob 95.00% • Move 4.00% • Priced-in 90.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ATI-052 Phase 1b asthma and atopic dermatitis readouts
2026-09-30
Management said both placebo-controlled Phase 1b trials remain ongoing and topline results are expected in the second half of 2026, making this the clearest near-term program-specific catalyst for whether the asset can support a rerating [#8-K-2026-05-07].
Prob 65% • Move 20% • Priced-in 40%
Bosakitug Phase 2 atopic dermatitis topline
2026-12-15
Enrollment is complete in the randomized Phase 2 atopic dermatitis study, and topline results are expected in the fourth quarter of 2026; this is the other major binary read on whether Aclaris can sustain development value alongside ATI-052 [#8-K-2026-05-07].
Prob 55% • Move 22% • Priced-in 35%

Risks

Clinical execution risk: ATI-052 and bosakitug both need clean efficacy/safety data to justify further rerating.
Financing and dilution risk remain present even with the reported runway, because development spend can rise if programs advance or expand.
Low coverage and no verified post-print analyst revision signal leave the market with limited external validation of the thesis.
Program concentration: the equity story still depends heavily on a small number of clinical assets, so any trial miss can reset valuation quickly.

Peers

Symbol	Summary
CLYM	A small-cap, event-driven biotech with readout and financing sensitivity; closer as a volatility comparator than as an asset-portfolio match.
CRMD	A same-sector company with more operating ballast, useful as a check on how the market rewards clinical progress versus commercial durability.
IRWD	A broader biopharma comparator with more revenue scale, but still useful for gauging how much value the market assigns to late-stage pipeline optionality.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-27

Loading AI feed…

Symbol

Summary

CLYM

A small-cap, event-driven biotech with readout and financing sensitivity; closer as a volatility comparator than as an asset-portfolio match.

CRMD

A same-sector company with more operating ballast, useful as a check on how the market rewards clinical progress versus commercial durability.

IRWD

A broader biopharma comparator with more revenue scale, but still useful for gauging how much value the market assigns to late-stage pipeline optionality.